Xvivo Perfusion AB (XVIVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xvivo Perfusion AB (XVIVO) has a cash flow conversion efficiency ratio of 0.030x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr65.34 Million ≈ $7.03 Million USD) by net assets (Skr2.17 Billion ≈ $233.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See XVIVO defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Xvivo Perfusion AB - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Xvivo Perfusion AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xvivo Perfusion AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xvivo Perfusion AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Nanshan Zhishang Sci-Tech Co.Ltd.
SHE:300918
|
-0.024x |
|
Anteris Technologies Global Corp. Common Stock
NASDAQ:AVR
|
-0.103x |
|
Run Long Construction Co Ltd
TW:1808
|
0.308x |
|
Zhejiang Jingxing Paper Joint Stock Co Ltd
SHE:002067
|
0.019x |
|
INDIA SHELTER FINANCE CORPORATION LIMITED
NSE:INDIASHLTR
|
-0.061x |
|
Fujian Longxi Bearing Group Co Ltd
SHG:600592
|
0.011x |
|
Walton Advanced Engineering Inc
TW:8110
|
0.016x |
|
YD More Investments Ltd
TA:MRIN
|
-0.004x |
Annual Cash Flow Conversion Efficiency for Xvivo Perfusion AB (2011–2025)
The table below shows the annual cash flow conversion efficiency of Xvivo Perfusion AB from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see XVIVO market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr2.11 Billion ≈ $227.44 Million |
Skr101.07 Million ≈ $10.88 Million |
0.048x | -7.33% |
| 2024-12-31 | Skr2.16 Billion ≈ $232.10 Million |
Skr111.29 Million ≈ $11.98 Million |
0.052x | +116.83% |
| 2023-12-31 | Skr1.95 Billion ≈ $209.32 Million |
Skr46.29 Million ≈ $4.98 Million |
0.024x | +22.18% |
| 2022-12-31 | Skr1.43 Billion ≈ $153.91 Million |
Skr27.86 Million ≈ $3.00 Million |
0.019x | +307.63% |
| 2021-12-31 | Skr1.29 Billion ≈ $138.33 Million |
Skr-12.06 Million ≈ $-1.30 Million |
-0.009x | +22.87% |
| 2020-12-31 | Skr1.01 Billion ≈ $108.53 Million |
Skr-12.27 Million ≈ $-1.32 Million |
-0.012x | -123.81% |
| 2019-12-31 | Skr577.52 Million ≈ $62.15 Million |
Skr29.50 Million ≈ $3.18 Million |
0.051x | +16.87% |
| 2018-12-31 | Skr540.48 Million ≈ $58.16 Million |
Skr23.63 Million ≈ $2.54 Million |
0.044x | -0.64% |
| 2017-12-31 | Skr504.33 Million ≈ $54.27 Million |
Skr22.19 Million ≈ $2.39 Million |
0.044x | +10.93% |
| 2016-12-31 | Skr316.41 Million ≈ $34.05 Million |
Skr12.55 Million ≈ $1.35 Million |
0.040x | -14.52% |
| 2015-12-31 | Skr184.87 Million ≈ $19.90 Million |
Skr8.58 Million ≈ $923.13K |
0.046x | +318.52% |
| 2014-12-31 | Skr176.18 Million ≈ $18.96 Million |
Skr-3.74 Million ≈ $-402.59K |
-0.021x | -115.24% |
| 2013-12-31 | Skr96.64 Million ≈ $10.40 Million |
Skr13.46 Million ≈ $1.45 Million |
0.139x | +641.01% |
| 2012-12-31 | Skr88.77 Million ≈ $9.55 Million |
Skr1.67 Million ≈ $179.61K |
0.019x | -98.42% |
| 2011-12-31 | Skr11.91 Million ≈ $1.28 Million |
Skr14.17 Million ≈ $1.52 Million |
1.190x | -- |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more